Palisade Bio (PALI) Cash from Financing Activities (2010 - 2026)
Palisade Bio (PALI) reported Cash from Financing Activities of $3.1 million for Q1 2026, up 1314.34% year-over-year from $221516.6 in Q1 2025, and down 97.61% on a QoQ basis from $131.3 million in Q4 2025.
Palisade Bio (PALI) has 17 years of Cash from Financing Activities data on file, last reported at $3.1 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 1314.34% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $137.8 million (up 1788.1% YoY) and the FY2025 annual result came in at $134.4 million, up 1303.05% from the prior year.
- Cash from Financing Activities fell to $3.1 million in Q1 2026 per PALI's latest filing, from $131.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $131.3 million in Q4 2025 and bottomed at -$258000.0 in Q1 2025.
- The 5-year median for Cash from Financing Activities is $2.0 million (2024), against an average of $10.2 million.
- The widest annual swing landed in 2023, when Cash from Financing Activities surged 5203.45%; it then slumped 112.75% in 2025.
- Tracing PALI's Cash from Financing Activities over 5 years: stood at $1.7 million in 2022, then sank by 107.82% to -$134000.0 in 2023, then surged by 3205.97% to $4.2 million in 2024, then jumped by 3055.48% to $131.3 million in 2025, then sank by 97.61% to $3.1 million in 2026.
- Per Business Quant, the three latest PALI Cash from Financing Activities figures stand at $3.1 million (Q1 2026), $131.3 million (Q4 2025), and $3.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | 3.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.13 Mn |
| Mar 31, 2026 | 3.13 Mn |
| Dec 31, 2025 | 131.33 Mn |
| Dec 31, 2025 | 131.33 Mn |
| Sep 30, 2025 | 3.36 Mn |
| Sep 30, 2025 | 3.36 Mn |
| Jun 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | -258,000.00 |
| Mar 31, 2025 | -258,000.00 |
| Dec 31, 2024 | 4.16 Mn |
| Dec 31, 2024 | 4.16 Mn |
| Sep 30, 2024 | -180,000.00 |
| Sep 30, 2024 | -180,000.00 |
| Jun 30, 2024 | 3.58 Mn |
| Jun 30, 2024 | 3.58 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | -134,000.00 |
| Dec 31, 2023 | -134,000.00 |
| Sep 30, 2023 | 1.57 Mn |
| Sep 30, 2023 | 1.57 Mn |
| Jun 30, 2023 | 5.31 Mn |
| Jun 30, 2023 | 5.31 Mn |
| Mar 31, 2023 | 4.44 Mn |
| Mar 31, 2023 | 4.44 Mn |
| Dec 31, 2022 | 1.71 Mn |
| Dec 31, 2022 | 1.71 Mn |
| Sep 30, 2022 | 12.05 Mn |
| Sep 30, 2022 | 12.05 Mn |
| Jun 30, 2022 | 1.59 Mn |
| Jun 30, 2022 | 1.59 Mn |
| Mar 31, 2022 | -87,000.00 |
| Mar 31, 2022 | -87,000.00 |
| Dec 31, 2021 | -554,000.00 |
| Dec 31, 2021 | -554,000.00 |
| Sep 30, 2021 | 4.55 Mn |
| Sep 30, 2021 | 4.55 Mn |
| Jun 30, 2021 | 19.47 Mn |
| Jun 30, 2021 | 19.47 Mn |
| Mar 31, 2021 | 1.15 Mn |
| Mar 31, 2021 | 1.15 Mn |
| Dec 31, 2020 | 1.51 Mn |
| Dec 31, 2020 | 1.51 Mn |
| Sep 30, 2020 | 100,000.00 |
| Sep 30, 2020 | 100,000.00 |
| Jun 30, 2020 | -6.31 Mn |
| Jun 30, 2020 | -6.31 Mn |
| Mar 31, 2020 | 6.59 Mn |
| Mar 31, 2020 | 6.59 Mn |
| Dec 31, 2019 | -136,727.00 |
| Dec 31, 2019 | -136,727.00 |
| Sep 30, 2019 | 6.92 Mn |
| Sep 30, 2019 | 6.92 Mn |
| Jun 30, 2019 | -78,850.00 |
| Jun 30, 2019 | -78,850.00 |
| Mar 31, 2019 | -117,019.00 |
| Mar 31, 2019 | -117,019.00 |
| Dec 31, 2018 | 1.71 Mn |
| Dec 31, 2018 | 1.71 Mn |
| Sep 30, 2018 | 311,397.00 |
| Sep 30, 2018 | 311,397.00 |
| Jun 30, 2018 | -105,392.00 |
| Jun 30, 2018 | -105,392.00 |
| Mar 31, 2018 | -104,244.00 |
| Mar 31, 2018 | -104,244.00 |
| Dec 31, 2017 | -103,108.00 |
| Dec 31, 2017 | -103,108.00 |
| Sep 30, 2017 | 5.95 Mn |
| Sep 30, 2017 | 5.95 Mn |
| Jun 30, 2017 | -1.77 Mn |
| Jun 30, 2017 | -1.77 Mn |
| Mar 31, 2017 | 921,696.00 |
| Mar 31, 2017 | 921,696.00 |
| Dec 31, 2016 | 18.63 Mn |
| Dec 31, 2016 | 18.63 Mn |
| Sep 30, 2016 | -977,673.00 |
| Sep 30, 2016 | -977,673.00 |
| Jun 30, 2016 | 7.18 Mn |
| Jun 30, 2016 | 7.18 Mn |
| Mar 31, 2016 | -1.10 Mn |
| Mar 31, 2016 | -1.10 Mn |
| Dec 31, 2015 | -1.96 Mn |
| Dec 31, 2015 | -1.96 Mn |
| Sep 30, 2015 | 1.00 |
| Sep 30, 2015 | 1.00 |
| Jun 30, 2015 | -46,828.00 |
| Jun 30, 2015 | -46,828.00 |
| Mar 31, 2015 | 5.89 Mn |
| Mar 31, 2015 | 5.89 Mn |
| Dec 31, 2014 | 4.13 Mn |
| Dec 31, 2014 | 4.13 Mn |
| Sep 30, 2014 | -90,670.00 |
| Sep 30, 2014 | -90,670.00 |
| Jun 30, 2014 | -528,826.00 |
| Jun 30, 2014 | -528,826.00 |
| Mar 31, 2014 | 19.43 Mn |
| Mar 31, 2014 | 19.43 Mn |
| Dec 31, 2013 | 3.01 Mn |
| Dec 31, 2013 | 3.01 Mn |
| Sep 30, 2013 | 7.68 Mn |
| Sep 30, 2013 | 7.68 Mn |
| Jun 30, 2013 | 2.01 Mn |
| Jun 30, 2013 | 2.01 Mn |
| Mar 31, 2013 | 7.83 Mn |
| Mar 31, 2013 | 7.83 Mn |
| Dec 31, 2012 | 155,182.00 |
| Dec 31, 2012 | 155,182.00 |
| Sep 30, 2012 | 8.79 Mn |
| Sep 30, 2012 | 8.79 Mn |
| Jun 30, 2012 | -45,000.00 |
| Jun 30, 2012 | -45,000.00 |
| Mar 31, 2012 | 4.92 Mn |
| Mar 31, 2012 | 4.92 Mn |
| Sep 30, 2011 | -1.00 |
| Sep 30, 2011 | -1.00 |
| Mar 31, 2011 | 1.67 Mn |
| Mar 31, 2011 | 1.67 Mn |
| Dec 31, 2010 | 547,835.00 |
| Dec 31, 2010 | 547,835.00 |
| Sep 30, 2010 | 3,958.00 |
| Sep 30, 2010 | 3,958.00 |